Urapidil

Urapidil

SCHEMBL48992

COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 1.00
DRD2 P14416 7/20 1.00
ADRA1A P35348 5/20 1.00
DRD3 P35462 4/20 1.00
ADRA2A P08913 3/20 1.00
ADRA2B P18089 3/20 1.00
ADRA2C P18825 3/20 1.00
MAPT P10636 2/20 1.00
CYP3A4 P08684 2/20 1.00
HRH1 P35367 2/20 1.00
HTR2B P41595 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP2C19 P33261 2/20 1.00
LMNA P02545 1/20 1.00
ADRB2 P07550 1/20 1.00
ADRB1 P08588 1/20 1.00
TSHR P16473 1/20 1.00
MAPK1 P28482 1/20 1.00
SLC6A4 P31645 1/20 1.00
PDE3A Q14432 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Urapidil SCHEMBL29363219 1.00 HTR1A (1.00) HTR1ADRD2ADRA1ADRD3ADRA2A
Urapidil SCHEMBL30426045 0.99 MAPT (1.00) HTR1ADRD2ADRA1ADRD3ADRA2A
Urapidil SCHEMBL1321654 0.99 MAPT (1.00) HTR1ADRD2ADRA1ADRD3ADRA2A
SCHEMBL13532733 0.97 HTR1A (0.94) HTR1ADRD2ADRA1ADRD3ADRA2A
Urapidil SCHEMBL28768392 0.95 DRD2 (0.91) HTR1ADRD2ADRA1ADRD3ADRA2A
Urapidil SCHEMBL28768407 0.92 DRD2 (0.84) HTR1ADRD2ADRA1ADRD3ADRA2A
SCHEMBL7801565 0.90 DRD2 (0.81) HTR1ADRD2ADRA1ADRD3ADRA2A
SCHEMBL9428413 0.85 ADRA1A (0.74) HTR1ADRD2ADRA1ADRD3ADRA2A
Hydrochloric Acid SCHEMBL28284797 0.84 MAPT (0.73) HTR1ADRD2ADRA1ADRD3ADRA2A
SCHEMBL13532743 0.82 HTR1A (0.70) HTR1ADRD2ADRA1ADRD3ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7876 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106952-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION CDG CARE (US) 2026-05-21 WO claimed
CN-122032132-A Real-time crystal form control method and process control system for urapidil crystallization process 广东京豪生物制药有限公司 2026-05-15 CN claimed
EP-4731194-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP Technologies, Inc. (US) 2026-04-29 EP claimed
EP-4687805-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF CSP Technologies, Inc. (US) 2026-02-11 EP claimed
US-20260027008-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF CSP TECHNOLOGIES, INC. 2026-01-29 US claimed
WO-2025264260-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP TECHNOLOGIES, INC. (US) 2025-12-26 WO claimed
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS INC (US) 2025-09-25 US claimed
US-20250222008-A1 EYEDROPS CONTAINING AN ALPHA1-BLOCKER FOR INHIBITING MYOPIA PROGRESSION TSUBOTA LABORATORY, INC. (JP) 2025-07-10 US claimed
EP-4582103-A1 alpha1 BLOCKER-CONTAINING EYEDROPS FOR INHIBITING MYOPIA PROGRESSION Tsubota Laboratory, Inc. (JP) 2025-07-09 EP claimed
US-20250213647-A1 CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE UNIVERSITY OF SOUTH FLORIDA 2025-07-03 US claimed
EP-0513058-A1 USE OF KNOWN URACILES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROTECTION FROM AND TREATMENT OF DISEASES INVOLVING PROLIFERATIVE PROCESSES. BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1992-11-19 EP claimed
US-5145851-A Uracil derivative, side effect reduction HITACHI CHEMICAL CO., LTD. (JP) 1992-09-08 US claimed
WO-1992014453-A1 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1, INC. (US) 1992-09-03 WO claimed
WO-1992009273-A1 RETARDED-ACTION URAPIDIL FORMULATION BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1992-06-11 WO claimed
WO-1991011185-A1 USE OF URAPIDILE AND DERIVATIVES FOR TREATING ARTERIOSCLEROTIC DISEASES BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1991-08-08 WO claimed
EP-0416841-A2 Novel use of 6-[[3-[4-(2- methoxyphenyl)-1-piperazinyl] propyl]amino]-1,3-dimethyluracil for preparing a pharmaceutical for treating urinary obstruction HITACHI CHEMICAL CO., LTD. (JP) 1991-03-13 EP claimed
US-4988700-A Antiserotonin agent, aryl or heteroaryl piperazine compounds TROPONWERKE GMBH & CO. (DE) 1991-01-29 US claimed
EP-0275444-A1 Pharmaceutical form for urapidil BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1988-07-27 EP claimed
US-4747845-A POLYACRYLATES OR POLYACRYLAMIDE WITH SOLVENT AND HYDROGEN BONDING PLASTICIZER ENQUAY PHARMACEUTICAL ASSOCIATES (US) 1988-05-31 US claimed
US-4131678-A LOWER BLOOD PRESSURE BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1978-12-26 US claimed